Pfizer (PFE) and BioNTech SE Announce Positive Topline Results From an Ongoing Phase 3 Clinical Trial

Pfizer Inc. (NYSE:PFE) is one of the best growth stocks under $50 to buy now. On September 8, Pfizer Inc. (NYSE:PFE) and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort “evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19.”

Management reported that the preliminary data exhibited considerable growth in neutralizing antibodies targeting the LP.8.1 sublineage of SARS-CoV-2 after the vaccination, reinforcing pre-clinical data that supported the recent U.S. Food and Drug Administration (FDA) approval of the LP.8.1-adapted COVID-19 vaccine demonstrating improved immune responses against multiple circulating SARS-CoV-2 sublineages.

Pfizer Inc. (NYSE:PFE) also reported that the vaccine’s safety profile was consistent with previous studies, and no new safety concerns were identified.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.